Jennifer Kao on How an FDA Program Reduced Clinical Development Times for Some Drugs

Subscribe to UnitedHealthcare's Community & State newsletter.

Health Affairs' Editor-in-Chief Alan Weil interviews Jennifer Kao of the University of California Los Angeles on her recent paper that explores the impact of the Food and Drug Administration's breakthrough therapy designation program on the reduction of late-stage drug development time.

Order the July 2024 issue of Health Affairs.

Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcasts free for everyone.

Subscribe to UnitedHealthcare's Community & State newsletter.